Lobeline - Yaupon Therapeutics

Drug Profile

Lobeline - Yaupon Therapeutics

Latest Information Update: 02 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yaupon Therapeutics
  • Developer National Institute of Mental Health
  • Class Alkaloids; Drug withdrawal therapies; Piperidines; Smoking cessation therapies
  • Mechanism of Action Dopamine release inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Drug abuse

Most Recent Events

  • 02 Nov 2006 Phase-II clinical trials in Drug abuse in USA (unspecified route)
  • 02 Nov 2004 Phase-I clinical trials in Drug abuse in USA (unspecified route)
  • 02 Nov 2004 Preclinical trials in Attention-deficit hyperactivity disorder in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top